MASL
DrugPatients treated with MASL lozenge
Other names: Maackia amurensis seed lectin
NCT Number: NCT04188665
This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Early Phase 1
New Jersey Medical School, Newark, New Jersey, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients treated with MASL lozenge
Other names: Maackia amurensis seed lectin
Patients treated with placebo lozenge
Time frame: 1 day.
Measure morphology and podoplanin (PDPN) expression by immunohistochemistry of cells included in initial biopsies of oral lesions in comparison to normal oral squamous epithelial cells (OSCCs). We selected patients with lesions that express robust levels of PDPN and notable dysplasia for inclusion in the study. Intensity was graded on a scale of 1 to 5 with 5 having the most dysplastic morphology and highest PDPN expression.
Time frame: 1 day
Evaluate and compare the PDPN expression and morphology of cells from included in resected oral lesions from patients treated with the experimental compound MASL or placebo. We will measure if MASL treatment decreases PDPN expression and normalizes morphology of OSCC cells on a defined scale of pathological examination by immunohistochemistry.
Rowan University
Other
Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04665843
Carcinoma, Carcinoma, Squamous Cell
La Jolla, California, United States
View Trial DetailsNCT05673577
Carcinoma, Carcinoma, Squamous Cell
Shanghai, China
View Trial DetailsNCT05482880
Behavior, Carcinoma
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT06549816
Adenocarcinoma Of Esophagus, Adnexal Diseases
Guangzhou, Guangdong, China
View Trial Details